Lenacapavir
Gilead Sciences Prepares for Summer 2025 Launch of Long-Acting HIV Prevention Drug Lenacapavir
Gilead Sciences, lenacapavir, HIV prevention, PrEP, long-acting injectable, FDA approval, HIV sales, clinical trials, PURPOSE studies
Battle for HIV PrEP Market: Gilead’s Twice-Yearly Injection Challenges GSK’s Apretude
HIV prevention, PrEP, lenacapavir, Apretude, long-acting injectables, Gilead Sciences, GSK, ViiV Healthcare
Gilead Sciences Surpasses Q3 Earnings and Sales Forecasts, Boosts Annual Outlook
Gilead Sciences, Q3 earnings, HIV drug sales, annual guidance, Biktarvy, Veklury, lenacapavir, HIV prevention
Gilead and Merck’s Investigational HIV Combo Shows Promising Long-Term Viral Suppression in Phase 2 Trial
HIV treatment, Weekly oral regimen, Islatravir, Lenacapavir, Viral suppression, Phase 2 clinical trial, Gilead Sciences, Merck & Co.
Gilead Expands HIV Drug Access, Yet Faces Criticism Over Exclusion of Middle-Income Countries
Gilead Sciences, HIV drug access, Lenacapavir, Generic licensing agreements, Middle-income countries exclusion, HIV prevention, Pre-exposure prophylaxis (PrEP)
Gilead Expands Access to Long-Acting HIV PrEP with Licensing Deals for Generic Lenacapavir
Gilead Sciences, lenacapavir, HIV PrEP, generic licensing, long-acting HIV prevention, global health access
Gilead’s Twice-Yearly Lenacapavir Shows 96% HIV Risk Reduction, Paving Way for Regulatory Filings
Gilead Sciences, Lenacapavir, HIV Prevention, Twice-Yearly PrEP, Regulatory Filings, PURPOSE 2 Trial
Gilead’s Twice-Yearly Lenacapavir Shows 96% HIV Risk Reduction, Eyes 2025 Launch for HIV Prevention
Lenacapavir, HIV Prevention, Twice-Yearly Injection, Gilead Sciences, PrEP, PURPOSE 1 and 2 Trials, Regulatory Filings, 2025 Launch
Gilead’s Twice-Yearly PrEP Drug Achieves 100% Efficacy in HIV Prevention
Gilead, PrEP, HIV prevention, lenacapavir, GSK, Apretude, HIV vaccine, HIV treatment